April 27, 2017

Novocure Reports First Quarter 2017 Financial Results and Provides Company Update

More than 1,260 active patients at March 31, 2017, an increase of 59 percent from March 31, 2016, and 16 percent from December 31, 2016 First quarter 2017 net revenues of $34.9 million, reflecting 167 percent growth versus first quarter 2016 and 15 percent growth versus fourth… Read More
learn more
April 27, 2017

Novocure Reports First Quarter 2017 Financial Results and Provides Company Update

More than 1,260 active patients at March 31, 2017, an increase of 59 percent from March 31, 2016, and 16 percent from December 31, 2016 First quarter 2017 net revenues of $34.9 million, reflecting 167 percent growth versus first quarter 2016 and 15 percent growth versus fourth… Read More
learn more
April 19, 2017

Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston

Data suggest combined modality treatment with TTFields and triplet combination chemotherapy may extend survival in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that four abstracts focusing on Tumor Treating Fields (TTFields) will be presented at the upcoming 69th American Academy of… Read More
learn more
April 19, 2017

Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston

Data suggest combined modality treatment with TTFields and triplet combination chemotherapy may extend survival in patients with recurrent glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced that four abstracts focusing on Tumor Treating Fields (TTFields) will be presented at the upcoming 69th American Academy of… Read More
learn more
April 17, 2017

CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence

Data show glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived longer than patients who received bevacizumab alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that data from a post hoc analysis of the EF-14 pivotal phase 3 clinical trial of Optune… Read More
learn more
April 17, 2017

CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence

Data show glioblastoma patients who received Optune in combination with bevacizumab at first recurrence lived longer than patients who received bevacizumab alone ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that data from a post hoc analysis of the EF-14 pivotal phase 3 clinical trial of Optune… Read More
learn more
April 2, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients

Final analyses provide unprecedented five-year survival advantage reinforcing Optune plus temozolomide as a combination treatment for glioblastoma patients Survival benefit was maintained in all patient subgroups, including those with the worst prognostic features ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today final results from its… Read More
learn more
April 2, 2017

Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients

Final analyses provide unprecedented five-year survival advantage reinforcing Optune plus temozolomide as a combination treatment for glioblastoma patients Survival benefit was maintained in all patient subgroups, including those with the worst prognostic features ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today final results from its… Read More
learn more